These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12756076)

  • 1. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Kaklamani VG; Gradishar WJ
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

  • 5. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
    Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
    Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Landucci E; Orlandini C
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
    Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
    Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin in combination with the taxanes.
    Trudeau M; Pagani O
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
    Ventura GJ
    J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
    [No Abstract]   [Full Text] [Related]  

  • 18. The expanding role of epirubicin in the treatment of breast cancer.
    Glück S
    Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.